GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TNF Pharmaceuticals Inc (LTS:0A8D) » Definitions » Net Cash per Share

TNF Pharmaceuticals (LTS:0A8D) Net Cash per Share : $0.54 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is TNF Pharmaceuticals Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). TNF Pharmaceuticals's Net Cash per Share for the quarter that ended in Dec. 2024 was $0.54.

The historical rank and industry rank for TNF Pharmaceuticals's Net Cash per Share or its related term are showing as below:

LTS:0A8D' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.35   Med: 21.98   Max: 22.85
Current: 0.35

During the past 5 years, the highest Price-to-Net-Cash Ratio of TNF Pharmaceuticals was 22.85. The lowest was 0.35. And the median was 21.98.

LTS:0A8D's Price-to-Net-Cash is ranked better than
96.57% of 846 companies
in the Biotechnology industry
Industry Median: 3.835 vs LTS:0A8D: 0.35

TNF Pharmaceuticals Net Cash per Share Historical Data

The historical data trend for TNF Pharmaceuticals's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TNF Pharmaceuticals Net Cash per Share Chart

TNF Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Net Cash per Share
-4.67 8.27 1.51 -0.08 0.54

TNF Pharmaceuticals Quarterly Data
Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.08 -1.17 -5.46 1.48 0.54

Competitive Comparison of TNF Pharmaceuticals's Net Cash per Share

For the Biotechnology subindustry, TNF Pharmaceuticals's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TNF Pharmaceuticals's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TNF Pharmaceuticals's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where TNF Pharmaceuticals's Price-to-Net-Cash falls into.


;
;

TNF Pharmaceuticals Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

TNF Pharmaceuticals's Net Cash per Share for the fiscal year that ended in Dec. 2024 is calculated as

Net Cash per Share (A: Dec. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(8.518-6.701-0)/3.364
=0.54

TNF Pharmaceuticals's Net Cash per Share for the quarter that ended in Dec. 2024 is calculated as

Net Cash per Share (Q: Dec. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(8.518-6.701-0)/3.364
=0.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TNF Pharmaceuticals  (LTS:0A8D) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


TNF Pharmaceuticals Net Cash per Share Related Terms

Thank you for viewing the detailed overview of TNF Pharmaceuticals's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


TNF Pharmaceuticals Business Description

Traded in Other Exchanges
Address
855 North Wolfe Street, Suite 601, Baltimore, MD, USA, 21205
TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.

TNF Pharmaceuticals Headlines

No Headlines